TrialGynecologic oncology2019

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.

Shannon N Westin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.